entertainment -WSS

entertainment

author：leisure time 2025-09-29 21:13:44 - browse：7769

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Has Bernie Sanders reached the limit of his pharma bullying effort?

WSS

As billionaires fund anti

HHS's proposed rule does nothing to address the climate crisis

As health system earnings go up, health insurance stocks go down

As pharma fights Medicare drug negotiation, hospitals, docs silent

Feds fine Medicare Advantage plans for overcharging members

Drug firms test therapies to halt Alzheimer’s before symptoms arise

knowledge

entertainment

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare explains how it will choose drugs for negotiation

Sports medicine is finally prioritizing gender equality

Feds fine Medicare Advantage plans for overcharging members

Continuity nursing helped my family in our darkest PICU moments

As pharma fights Medicare drug negotiation, hospitals, docs silent

In age of alternative facts, a scholarly course on calling out crap

What AAP's gender

Continuity nursing helped my family in our darkest PICU moments

Complete sequence of Y chromosome published for first time

hotspot

Departing Stanford president retracts two papers

2024 GOP presidential candidates spar over abortion in debate

As billionaires fund anti

AltruBio raises $225 million to develop ulcerative colitis drug

Welsh Carson private equity firm escapes from FTC antitrust case

Medicare explains how it will choose drugs for negotiation

explore

knowledge

hotspot

entertainment